FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors-Reference-Cited by-同舟云学术

FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors

Published:2003-09 Issue:3 Volume:16 Page:409-417
ISSN:1521-6926
Container-title:Best Practice & Research Clinical Haematology
language:en
Short-container-title:Best Practice & Research Clinical Haematology

Author:

Gilliland D.Gary

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Oncology

Reference44 articles.

1. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia;Nakao;Leukemia,1996

2. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia;Horiike;Leukemia,1997

3. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia;Stirewalt;Blood,2001

4. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children;Xu;British Journal of Haematology,1999

5. Internal tandem duplication in the juxtatransmembrane domain of the flt3 is not involved in blastic crisis of chronic myeloid leukemia;Iwai;Leukemia,1997

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules;RSC Medicinal Chemistry;2024

2. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases;European Journal of Medicinal Chemistry;2022-09

3. APL in Developing Countries: ATO-Based Approach;Acute Promyelocytic Leukemia;2017-09-26

4. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220;Cancer Research;2017-06-16

5. Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants;Journal of Medicinal Chemistry;2016-06-22